 Dyne Therapeutics Inc NASDAQ: DYN shares are trading lower by 5.42 to 6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of Duchenne muscular dystrophy. Dyne says the company plans to evaluate DYNE-251 in a global,. 